secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclarion, Inc. (ACON)
CIK:        0001635077
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001683168-23-006784
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclarion updates investor deck; highlights CLARITY trial start Q4 2023 with 300 patients
--------------------------------------------------------------------------------

- CLARITY prospective randomized trial begins Q4 2023; 300 patients, 42-month timeline, Johns Hopkins anchor site.
- NIH BACPAC studies (comeBACK, BEST) using Nociscan; enrollment ongoing, expected completion Q2 2024.
- CPT Category III codes 0609T and 0611T secured Jan 2021; early commercialization in progress.
- 39 issued US/international patents plus 13 pending; market opportunity up to $135B low back pain market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635077/000168316823006784/0001683168-23-006784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635077/000168316823006784/acon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-006784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer